NK1R antagonists (aprepitant/orvepitant) can be tested in COVID-19 cough because TRPV1 in sensory neurons is upregulated by various viral infections (human rhinovirus).[ 7 , 54 ] TRPV-1 antagonist (SB-705498) showed a significant improvement in cough reflex sensitivity to capsaicin at 2 hours and a borderline significant improvement at 24 hours.[ 55 ] Thalidomide has also shown promising results in controlling the disabling cough in ILD patients at a dose of 50–100 mg per day dosing.
1
—
—